OPR - Delayed Quote • USD KRYS May 2024 210.000 call (KRYS240517C00210000) Follow 1.1500 0.0000 (0.00%) At close: April 25 at 12:02 PM EDT Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw Table View List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Date Close Open High Low Volume O H L C Vol AAPL Loading Chart for KRYS240517C00210000 1D 5D 1M 3M 6M YTD 1Y 2Y 5Y All Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: KRYS Krystal Biotech to Report First Quarter 2024 Financial Results on May 6, 2024 Down -7.21% in 4 Weeks, Here's Why Krystal Biotech (KRYS) Looks Ripe for a Turnaround Krystal Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of Inhaled KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors of the Lung Krystal Biotech (KRYS) is on the Move, Here's Why the Trend Could be Sustainable Recent 3.8% pullback isn't enough to hurt long-term Krystal Biotech (NASDAQ:KRYS) shareholders, they're still up 437% over 5 years Krystal Biotech to Present at the American Association for Cancer Research 2024 Annual Meeting Recent Price Trend in Krystal Biotech (KRYS) is Your Friend, Here's Why 3 Strong Buy Biotech Stocks to Add to Your Q2 Must-Watch List Krystal Biotech, Inc. (KRYS) Is a Great Choice for 'Trend' Investors, Here's Why Can Krystal Biotech, Inc. (KRYS) Run Higher on Rising Earnings Estimates? What Makes Krystal Biotech, Inc. (KRYS) a New Buy Stock Krystal Biotech, Inc. (KRYS) is a Great Momentum Stock: Should You Buy?
